Research shows that there are currently 2 million U.S. women who regularly participate in the aesthetic injectables market, while approximately 17 million are considering aesthetic injectable treatment. Additionally, approximately 34 million US women purchase skin care products at their doctor's office annually.This collaboration provides a significant opportunity to leverage the overlapping markets, providing exposure to the population interested in both. It will increase access to aesthetic facial injectables and protective makeup products to more cosmetic and dermatology practices.
"Galderma is pleased to offer our current and future customers the opportunity to receive not only innovative facial injectables, but topline skincare solutions as well," said Alisa Lask, vice president, US marketing, aesthetic and corrective business unit, Galderma, US.
The marketing collaboration will include certain brands of Galderma's aesthetic facial injectables and some of Colorescience's most popular cosmetic and skincare products in the U.S. market. The Galderma and Colorescience collaboration will leverage both companies' consumer expertise and continued commitment to innovative skincare solutions.
"As a company dedicated to the creation of prestige skin health products that promote 365-day protection from UV rays and environmental stressors to enhance beauty without compromise, we're thrilled to partner with Galderma to offer products to healthcare professionals and women looking for health-forward skincare solutions," said Mary Fisher, president and CEO, Colorescience.
Through this new collaboration, the two companies will seek opportunities to leverage their combined consumer expertise and market growth strategies to benefit both healthcare professionals and consumers. This will include the industry-leading ASPIRE Galderma Rewards loyalty program (www.aspirerewards.com), and Lasting Beauty Rewards (www.colorescience.com/rewards).